Latest Epidermal growth factor receptor Stories
CALGARY, Sept. 2 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S.
The central role of receptor tyrosine kinases (RTKs) in cellular processes, especially in cancer, has made them an important target for several antibody- and small molecule-based inhibitors specific for various RTKs for the treatment of different tumour entities.
MISSISSAUGA, ON, Aug. 4 /PRNewswire-FirstCall/ -- YM BioSciences Inc.
Cyclacel Pharmaceuticals, Inc.
* Alocrest(tm) Phase 1 Data Demonstrates Potential for Improved Safety and Efficacy Compared to Conventional Vinorelbine * Menadione Topical Lotion Restores Kinase Activity and Does Not Inhibit the Anti-Tumor Effect of Erlotinib (Tarceva(r)) in Preclinical Models SOUTH SAN FRANCISCO, Calif., July 7, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, presented data for two of the company's...
Clarient has launched its new offering, Kras, which has been validated as a laboratory-developed test to be used as a predictive molecular biomarker for patients with colorectal cancer.
Takeda Pharmaceutical and Takeda Bio Development Center have submitted a new drug application of anti-cancer agent, panitumumab for the treatment of patients with progressed or relapse colorectal cancer to the Ministry of Health Labour and Welfare in Japan.
SOUTH SAN FRANCISCO, Calif., June 23, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it will present pre-clinical data on Menadione Topical Lotion and clinical data on Alocrest(tm) (vinorelbine liposomes injection, OPTISOME(tm)) at the European Society for Medical Oncology (ESMO) Conference taking place July 3-6, 2008 in Lugano, Switzerland.
Response Genetics, Inc. (NASDAQ: RGDX) announced today that its ResponseDX: Lung™ and ResponseDX: Colon™ tests are now available to select medical institutions and practice groups through its CLIA-registered laboratory.
- The parings of haberdine; also, any kind of fragments.